Long-Acting HIV Drug Shows Promise

Regular injections of an antiretroviral drug protects macaques from simian-human immunodeficiency virus infection, researchers report.

By | March 6, 2014

WIKIMEDIA, NIHFormulated as a long-acting injectable and given every three months, the integrase strand-transfer inhibitor GSK744 protected macaques from simian-human immunodeficiency virus (SHIV), researchers from Rockefeller University, GlaxoSmithKline, and the Tulane National Primate Research Center reported in Science this week (March 4). Separately, a team from the US Centers for Disease Control and Prevention (CDC) studying the effects of GSK744 in female monkeys reached a similar conclusion. Both groups presented their results at the CDC’s annual Conference on Retroviruses and Opportunistic Infections held in Boston this week.

“If the findings can be replicated in humans, they have the potential to overcome a major problem in AIDS prevention: that many people fail to take their antiretroviral pills regularly,” The New York Times reported.

Efforts to develop an HIV vaccine continue, but the team behind the Science study said a long-acting injectable drug could improve upon current treatments. Still, compliance may still be a problem, Philip Johnson of the Children’s Hospital of Philadelphia in Pennsylvania told ScienceNow. “This is going to require multiple injections over the lifetime of an individual,” he said, asking: “How feasible is it truly in the long term?”

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham